Lupin inches up on launching Bromfenac Ophthalmic Solution
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 1398.40, up by 2.35 points or 0.17% from its previous closing of Rs. 1396.05 on the BSE.
The scrip opened at Rs. 1412.50 and has touched a high and low of Rs. 1414.95 and Rs. 1396.05 respectively. So far 5710 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1429.95 on 05-Jan-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1429.95 and Rs. 1375.75 respectively. The current market cap of the company is Rs. 63565.86 crore.
The promoters holding in the company stood at 47.06%, while Institutions and Non-Institutions held 44.42% and 8.52% respectively.
Lupin has launched Bromfenac Ophthalmic Solution, 0.07%, after having received an approval from the United States Food and Drug Administration (USFDA). Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity.
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution (RLD Prolensa) had estimated annual sales of $182 million in the U.S. (IQVIA MAT November 2023).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
